Form D · Pharmaceuticals
Pattern Pharma Inc.
Toronto, A6 · CIK 0001759778
Offering snapshot reported Aug 27, 2024 · SEC filing
- Reported sold
- $275K Offering amount: $275K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 15, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 27, 2024 | Initial | $275,000 | No comparison | 2 | SEC filing |
| Jul 28, 2021 | Amendment | $1,498,325 | No comparison | Not reported | SEC filing |
| Jul 21, 2021 | Amendment | $983,325 | No comparison | Not reported | SEC filing |
| May 26, 2021 | Initial | $150,000 | No comparison | 1 | SEC filing |
| May 11, 2021 | Amendment | $1,650,000 | $1,600,000vs Apr 30, 2021 | 3 | SEC filing |
| Apr 30, 2021 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Sep 23, 2020 | Amendment | $570,000 | $70,000vs Aug 12, 2020 | 2 | SEC filing |
| Aug 12, 2020 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Jan 15, 2020 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Dec 13, 2019 | Initial | $75,000 | No comparison | 1 | SEC filing |
| Nov 27, 2018 | Initial | $40,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-522515
This Special Equity Right Certificate represents the right for the investment to automatically convert into shares of the Issuer.
Source: Form D, filed Aug 27, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Abeles | Director |
| Nick Glover | Executive |
| Nicholas Glover | Director |
| Hans Keirstead | Director |
| Hans Kierstead | Director |
| Mark Frans Van Coeverden De Groot | Director, Executive |
| Andrew Williams | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
199 Bay Street Suite 4000
Toronto, A6, M5L 1A9
Toronto, A6, M5L 1A9